ArticleNeuro-oncology2022

Trabectedin for recurrent WHO grade 2 or 3 meningiomas-Paving the road for new opportunities.

Christopher A Alvarez-Breckenridge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.